Literature DB >> 24957246

WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.

Alberto Alvarez-Larrán1, Agueda Ancochea, Mar García, Fina Climent, Francesc García-Pallarols, Anna Angona, Alicia Senín, Carlos Barranco, Luz Martínez-Avilés, Sergio Serrano, Beatriz Bellosillo, Carlos Besses.   

Abstract

Bone marrow histology is included in the diagnostic criteria of myeloproliferative neoplasms (MPNs). However, some concerns have emerged about its reproducibility. To evaluate the diagnostic accuracy of histology and to assess its correlation with presence of mutations and clinical outcomes, two pathologists reviewed the bone marrow biopsies corresponding to 211 patients with MPN. Despite the low agreement in the evaluation of individual histopathological characteristics, the concordance among pathologists when establishing the diagnosis was good (Kappa index 0·67). The specificity of histology was 100%, 98·5% and 98% in polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), respectively, whereas the sensitivity of histological diagnosis was low in PV and ET (32·5% and 54% respectively) and acceptable in PMF (75%). Thirteen out of 146 (9%) patients with clinical ET were diagnosed as prefibrotic PMF. No histological agreement or MPN otherwise unspecified was more frequently observed in JAK2 V617F-positive ET than in CALR-mutated cases, whereas megakaryocytic abnormalities and prefibrotic PMF were more frequently observed in CALR-mutated ET. In conclusion, histological criteria of MPN have a limited diagnostic accuracy due to low sensitivity. Patients with JAK2 V617F-positive MPN have a heterogeneous histology while CALR-positive ET is associated with megakaryocyte abnormalities and prefibrotic PMF.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  CALR; JAK2 V617F; bone marrow histology; myelopoliferative neoplasms; prefibrotic myelofibrosis

Mesh:

Substances:

Year:  2014        PMID: 24957246     DOI: 10.1111/bjh.12990

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 2.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

Review 3.  The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control.

Authors:  Alessandro Malara; Vittorio Abbonante; Christian A Di Buduo; Lorenzo Tozzi; Manuela Currao; Alessandra Balduini
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

4.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

5.  Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.

Authors:  Gene Shaw; Richard Berg
Journal:  Clin Med Res       Date:  2019-10-03

6.  Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.

Authors:  Korsuk Sirinukunwattana; Alan Aberdeen; Helen Theissen; Nikolaos Sousos; Bethan Psaila; Adam J Mead; Gareth D H Turner; Gabrielle Rees; Jens Rittscher; Daniel Royston
Journal:  Blood Adv       Date:  2020-07-28

7.  Burning feet in polycythemia vera - peripheral sensorimotor axonal neuropathy with erythromelalgia.

Authors:  Uwe Wollina
Journal:  Int J Gen Med       Date:  2015-02-02

8.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 9.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

Review 10.  Guidelines for the management of myeloproliferative neoplasms.

Authors:  Chul Won Choi; Soo-Mee Bang; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Soo-Jeong Kim; Yeo-Kyeoung Kim; Jinny Park; Jong-Ho Won
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.